The objective of this report is to describe a rare case of durvalumab-induced hypoparathyroidism.<h4>Case report</h4>We describe a case of a 64-year-old man who presented to the emergency department with acute symptomatic hypocalcemia 2 years after completion of durvalumab treatment for stage III non-small cell lung cancer, who had a suppressed parathyroid hormone level, which persisted with correction of calcium levels.<h4>Discussion</h4>ICI-induced hypoparathyroidism is a rare entity with only few cases reported in the literature, the mechanism for which remains unclear. The gene discussed is PTH; the disease is non-small cell lung carcinoma.